184 related articles for article (PubMed ID: 11235226)
21. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
22. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
Bono AV; DiSilverio F; Robustelli della Cuna G; Benvenuti C; Brausi M; Ferrari P; Gibba A; Galli L
Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140
[TBL] [Abstract][Full Text] [Related]
23. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
25. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
26. [Endometrioid adenocarcinoma of the prostate: report of 3 cases].
Uemura M; Nakagawa M; Kanno N; Nishimura K; Miyoshi S; Kawano K
Hinyokika Kiyo; 2004 Nov; 50(11):825-8. PubMed ID: 15628548
[TBL] [Abstract][Full Text] [Related]
27. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
28. [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].
Yoshida T; Nishimura K; Uemura M; Nakagawa K; Harada Y; Kanno N; Miyoshi S; Kawano K
Hinyokika Kiyo; 2006 Nov; 52(11):891-4. PubMed ID: 17176877
[TBL] [Abstract][Full Text] [Related]
29. Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
Cusan L; Gomez JL; Dupont A; Diamond P; Lemay M; Moore S; Labrie F
Prostate; 1994 May; 24(5):257-61. PubMed ID: 7513417
[TBL] [Abstract][Full Text] [Related]
30. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
32. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
[TBL] [Abstract][Full Text] [Related]
33. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
[TBL] [Abstract][Full Text] [Related]
34. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
35. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
36. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
El-Gabry EA; Strup SE; Gomella LG
Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
[TBL] [Abstract][Full Text] [Related]
37. [A case of prostate cancer with multiple pulmonary metastases].
Katoh H; Yamamoto N; Harada Y; Chang PK; Takeuchi T; Kanematsu M; Kuriyama M; Ban Y; Matsui E
Hinyokika Kiyo; 1987 Mar; 33(3):441-6. PubMed ID: 3618415
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
Behrakis P; Koutsilieris M
Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
[TBL] [Abstract][Full Text] [Related]
40. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
